Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stake Boosted by Oberweis Asset Management Inc.

Oberweis Asset Management Inc. lifted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 14.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 184,595 shares of the company's stock after purchasing an additional 23,440 shares during the period. Oberweis Asset Management Inc. owned about 0.38% of Amphastar Pharmaceuticals worth $6,854,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Hsbc Holdings PLC raised its holdings in shares of Amphastar Pharmaceuticals by 23.4% during the fourth quarter. Hsbc Holdings PLC now owns 8,991 shares of the company's stock worth $330,000 after purchasing an additional 1,707 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Amphastar Pharmaceuticals by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after buying an additional 348 shares in the last quarter. MetLife Investment Management LLC lifted its position in Amphastar Pharmaceuticals by 3.7% during the fourth quarter. MetLife Investment Management LLC now owns 23,452 shares of the company's stock worth $871,000 after buying an additional 845 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Amphastar Pharmaceuticals by 9.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock worth $44,503,000 after buying an additional 105,288 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in Amphastar Pharmaceuticals by 350.0% during the fourth quarter. First Trust Advisors LP now owns 81,129 shares of the company's stock worth $3,012,000 after buying an additional 63,100 shares during the period. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Trading Up 0.4 %

AMPH traded up $0.09 on Tuesday, reaching $24.50. 296,368 shares of the company's stock were exchanged, compared to its average volume of 464,603. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a twelve month low of $22.64 and a twelve month high of $53.96. The company's 50 day moving average is $26.91 and its 200-day moving average is $36.27. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 8.17, a PEG ratio of 2.19 and a beta of 0.79.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AMPH. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Friday, March 21st.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.